Unresectable Melanoma
Also known as: Melanoma Unresectable
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB11595 | Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
| DB11967 | Binimetinib | A medication used to treat metastatic melanoma with specific mutations. |
| DB05239 | Cobimetinib | An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. |
| DB08912 | Dabrafenib | A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. |
| DB11718 | Encorafenib | A kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations. |
| DB06186 | Ipilimumab | A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. |
| DB17107 | Lifileucel | An autologous T cell immunotherapy used to treat unresectable or metastatic melanoma in previously treated adults. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB14851 | Relatlimab | A monoclonal antibody targeted against LAG-3 which is used in combination with nivolumab for the treatment of unresectable or metastatic melanoma. |
| DB08911 | Trametinib | A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer. |
| DB08881 | Vemurafenib | A kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation. |